Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)

被引：0
|
作者：
Kim, T. M. [1 ]
Girard, N. [2 ]
Low, G. K. M. [3 ]
Zhuo, J. [4 ]
Yu, D. Y. [5 ]
Yang, Y. [4 ]
Murota, M. [6 ]
Lim, C. [7 ]
Kleinman, N. J. [8 ]
Cho, B. C. [9 ]
机构：
[1] Seoul Natl Univ Hosp, Hemato Oncol, Seoul, South Korea
[2] Inst Curie, Thorax Inst, Paris, France
[3] Janssen Asia Pacific, Med Affairs, Singapore, Singapore
[4] Janssen China, Res & Dev, Shanghai, Peoples R China
[5] Janssen Asia Pacific, Real World Evidence, Singapore, Singapore
[6] Janssen Res & Dev, Med Affair Operat, Global Dev, Tokyo, Japan
[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore
[8] IQVIA Hong Kong, Real World Solut, Hong Kong, Peoples R China
[9] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1109p
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [31] Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
    Shi, Chao
    Xing, Ruyue
    Li, Mengmeng
    Feng, Junnan
    Sun, Rui
    Wei, Bing
    Guo, Yongjun
    Ma, Jie
    Wang, Huijuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
    Xie, Yuhao
    Lu, Qisi
    Wang, Jing-Quan
    Bo, Letao
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    DRUGS OF TODAY, 2022, 58 (08) : 389 - 398
  • [33] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
    Minchom, Anna
    Viteri, Santiago
    Bazhenova, Lyudmila
    Gadgeel, Shirish M.
    Ou, Sai-Hong Ignatius
    Trigo, Jose
    Bauml, Joshua M.
    Backenroth, Daniel
    Bhattacharya, Archan
    Li, Tracy
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2022, 168 : 74 - 82
  • [34] Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
    Wang, Yue
    Li, Jingwen
    Zhou, Yan
    Cao, Shuhui
    Ling, Xuxinyi
    Zhang, Yao
    Nie, Wei
    Zhong, Hua
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (20)
  • [35] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [36] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
  • [37] Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214
  • [38] Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab
    Jatkoe, Timothy
    Wang, Songbai
    Odegaard, Justin I.
    Roth, Anne Marie Velasco
    Osgood, Drew
    Martinez, Gabriela
    Lucas, Paul
    Curtin, Joshua C.
    Karkera, Jayaprakash
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (11): : 1181 - 1188
  • [39] Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
    Zhang, Mai
    Huang, Qian
    Yu, Min
    Xue, Jianxin
    Huang, Meijuan
    Lu, You
    Zhang, Yan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (04) : 797 - 807
  • [40] Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
    Li, Jiaqi
    Xie, Mengqing
    Zhao, Ruiying
    Qiang, Huiping
    Chang, Qing
    Qian, Jialin
    Lu, Haijiao
    Shen, Yinchen
    Han, Yuchen
    Su, Chunxia
    Chu, Tianqing
    FRONTIERS IN ONCOLOGY, 2024, 14
12345